Phase 2 Study Demonstrates Oral Rilzabrutinib Reduces Loss of Control Events in Patients With Asthma
Positive results from a phase 2 trial (NCT05104892) demonstrate that treatment with oral rilzabrutinib at both a high and low dose led to a numerical reduction in loss of asthma control (LOAC) events. The results were presented at the 2024 American …